Aptose Biosciences(APTO) - 2025 Q3 - Quarterly Results

EXHIBIT 99.1 Aptose Reports Third Quarter 2025 Results SAN DIEGO and TORONTO, Nov. 13, 2025 (GLOBE NEWSWIRE) -- Aptose Biosciences Inc. ("Aptose" or the "Company") (TSX: APS and OTC: APTOF), a clinical-stage precision oncology company developing a tuspetinib (TUS)-based triple drug frontline therapy to treat patients with newly diagnosed acute myeloid leukemia (AML), today announced financial results for the third quarter ended September 30, 2025, and provided a corporate update. "Tuspetinib in combination ...